BrightGene's oral dual agonist sees up to 8% weight loss at 8 weeks in slice of early data
BrightGene's oral dual agonist sees up to 8% weight loss at 8 weeks in slice of early data
Body unavailable. Use the original source.
BrightGene's oral dual agonist sees up to 8% weight loss at 8 weeks in slice of early data
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.